Back to discover
Disease

Smoldering plasma cell myeloma

Late-stage therapeutic development
Also known as asymptomatic myeloma, asymptomatic plasma cell myeloma, smoldering Multiple myeloma/plasma cell myeloma, smoldering multiple myeloma+4 more

asymptomatic myeloma, asymptomatic plasma cell myeloma, smoldering Multiple myeloma/plasma cell myeloma, smoldering multiple myeloma, smoldering myeloma, smouldering Multiple myeloma/plasma cell myeloma, smouldering multiple myeloma, smouldering myeloma.

11
Clinical trials
1
Associated genes
1
Related proteins
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Accelerated approval: Darzalex (EMA)

Regulatory2016-05-20EMA

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 6 clinical trials expected to report results, the earliest in Q4 2026.
  • 1 industry development reported.
Upcoming Milestones
Major developments
Upcoming trial readoutHigh impact
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Results expected Q4 20292026-06-18
Upcoming trial readoutImportant
Iberdomide in Intermediate- and High-Risk Smoldering Myeloma (SMM) Patients: A Phase 2 Study With a Safety Run-in
Results expected Q3 20272026-06-01
Clinical Milestones7View
Results expected 5
Recently completed 1
Industry & Market1View
Activity timeline8

Clinical trials

7 sponsors · 0 new · 1 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
11
All trials
6
Active
1
Late-stage
2
Completed
Late-stage studies

Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)

Phase 3 · Recruiting · ECOG-ACRIN Cancer Research Group

Associated genes

1 match

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

CD380.36

Disease biology

1 match

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1via CD380.36

Reference

Authoritative identity, definition & identifiers.

Synonyms

asymptomatic myeloma, asymptomatic plasma cell myeloma, smoldering Multiple myeloma/plasma cell myeloma, smoldering multiple myeloma, smoldering myeloma, smouldering Multiple myeloma/plasma cell myeloma, smouldering multiple myeloma, smouldering myeloma

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.